About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

New Treatments Outperforming Placebo Becoming Less Common

Comparative effectiveness studies may be needed
FRIDAY, June 14 (HealthDay News) -- The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.
Mark Olfson, M.D., M.P.H., from Columbia University in New York City, and Steven C. Marcus, Ph.D., from the University of Pennsylvania in Philadelphia, randomly selected and analyzed 315 placebo-controlled trials published in BMJ, the Journal of the American Medical Association, The Lancet, and the New England Journal of Medicine from 1966 to 2010.
The researchers found that the average effect size or average difference in efficacy fell significantly between the active treatment and placebo, from a peak odds ratio of 4.51 (1971 to 1980) to 1.36 (2001 to 2010).
"A decline in effect sizes in conventional placebo-controlled trials supports an increased emphasis on other avenues of research, including comparative studies on the safety, tolerability, and cost of treatments with established efficacy," Olfson and colleagues conclude.
Abstract (http://content.healthaffairs.org/content/32/6/1116.abstract )Full Text (subscription or payment may be required) (http://content.healthaffairs.org/content/32/6/1116.full )
Health Headlines
Ragwitek Approved for Adult Ragweed AllergyView in a lightbox
Restaurants in Poor Areas Push Unhealthy Foods, Study FindsView in a lightbox
Certain Sedatives Tied to Breathing Problems in Older COPD PatientsView in a lightbox
Nurses' Experience Key to Better Patient Care, Study SaysView in a lightbox
Appetite, Taste Changes Reported After Weight-Loss SurgeryView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices